Evidence map›Paper›PMID 34911933›Full record

ArticleNature communications2021

Epigenetic loss of heterogeneity from low to high grade localized prostate tumours.

Sebnem Ece Eksi, Alex Chitsazan, Zeynep Sayar, George V Thomas, Andrew J Fields, Ryan P Kopp, Paul T Spellman, Andrew C Adey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Patterns of indolence in prostate cancer (Review).Experimental and therapeutic medicine · 2022
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Sebnem Ece EksiCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, 97239, USA. eksi@ohsu.edu.ORCID http://orcid.org/0000-0003-1012-5571
Alex ChitsazanCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, 97239, USA.
Zeynep SayarCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, 97239, USA.
George V ThomasCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, 97239, USA.ORCID http://orcid.org/0000-0001-7416-8840
Andrew J FieldsDepartment of Molecular and Medical Genetics, School of Medicine, OHSU, Portland, OR, 97239, USA.
Ryan P KoppDepartment of Urology, School of Medicine, OHSU, Portland, OR, 97239, USA.
Paul T SpellmanCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, 97239, USA.ORCID http://orcid.org/0000-0002-4810-0022
Andrew C AdeyCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, 97239, USA. adey@ohsu.edu.ORCID http://orcid.org/0000-0001-7648-8717
OHSU Knight Cancer InstituteOregon Health & Science University · USUniversity of Portland · US

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
NCI NIH HHS P30 CA069533
6 · The paper itself

Abstract

Identifying precise molecular subtypes attributable to specific stages of localized prostate cancer has proven difficult due to high levels of heterogeneity. Bulk assays represent a population-average, which mask the heterogeneity that exists at the single-cell level. In this work, we sequence the accessible chromatin regions of 14,424 single-cells from 18 flash-frozen prostate tumours. We observe shared chromatin features among low-grade prostate cancer cells are lost in high-grade tumours. Despite this loss, high-grade tumours exhibit an enrichment for FOXA1, HOXB13 and CDX2 transcription factor binding sites, indicating a shared trans-regulatory programme. We identify two unique genes encoding neuronal adhesion molecules that are highly accessible in high-grade prostate tumours. We show NRXN1 and NLGN1 expression in epithelial, endothelial, immune and neuronal cells in prostate cancer using cyclic immunofluorescence. Our results provide a deeper understanding of the active gene regulatory networks in primary prostate tumours, critical for molecular stratification of the disease.

Indexed as

Epigenesis, GeneticCalcium-Binding ProteinsCDX2 Transcription FactorCell Adhesion Molecules, NeuronalCohort StudiesGene Expression Regulation, NeoplasticGene Regulatory NetworksHepatocyte Nuclear Factor 3-alphaHomeodomain ProteinsHumansLoss of HeterozygosityMaleNeoplasm StagingNeural Cell Adhesion MoleculesProstatic NeoplasmsCalcium-Binding ProteinsCDX2 protein, humanCDX2 Transcription FactorCell Adhesion Molecules, NeuronalFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaHomeodomain ProteinsHOXB13 protein, humanNeural Cell Adhesion Moleculesneuroligin 1NRXN1 protein, human

Identifiers

PMID34911933
PMCPMC8674326
OpenAlexW4200449548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.